ZUTECTRA

This brand name is authorized in Austria, Croatia, Estonia, France, Ireland, Israel, Italy, Lithuania, Netherlands, Poland, Romania, Singapore, Spain, Turkey, UK.

Active ingredients

The drug ZUTECTRA contains one active pharmaceutical ingredient (API):

1	Hepatitis B, purified antigen UNII IFJ010MNE4 - HEPATITIS B VIRUS HBSAG SURFACE PROTEIN ANTIGEN
	Hepatitis B vaccine induces specific humoral antibodies against hepatitis B virus surface antigen (anti-HBsAg). Hepatitis B vaccine has been recognized as the first anti-cancer vaccine because it can prevent primary liver cancer.
	Read more about Hepatitis B, purified antigen

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ZUTECTRA Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J06BB04	Hepatitis B immunoglobulin	J Antiinfectives for systemic use → J06 Immune sera and immunoglobulins → J06B Immunoglobulins → J06BB Specific immunoglobulins
Discover more medicines within J06BB04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1453665
ES	Centro de información online de medicamentos de la AEMPS	09600001
FR	Base de données publique des médicaments	65527071
GB	Medicines & Healthcare Products Regulatory Agency	175259
IL	מִשְׂרַד הַבְּרִיאוּת	8357
IT	Agenzia del Farmaco	039644012
LT	Valstybinė vaistų kontrolės tarnyba	1052685
NL	Z-Index G-Standaard, PRK	96466
PL	Rejestru Produktów Leczniczych	100312920
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W56595001
SG	Health Sciences Authority	14651P
TR	İlaç ve Tıbbi Cihaz Kurumu	8699535980523